secwatch.observer — SEC 8-K summary
======================================

Issuer:     EKSO BIONICS HOLDINGS, INC. (CHRN)
CIK:        0001549084
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001437749-24-000621
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ekso Bionics prelim Q4 rev ~$4.8M (+31% YoY); FY rev ~$18.2M (+41% YoY); cash $8.6M
--------------------------------------------------------------------------------

- Q4 2023 revenue estimated $4.7-4.9M, up from $3.6M in Q4 2022 (30-36% YoY increase).
- FY 2023 revenue estimated $18.1-18.3M, up from $12.9M in FY 2022 (40-42% YoY increase).
- Cash at Dec 31, 2023 estimated $8.6M vs $20.5M a year ago; Q4 cash burn improved to $1.7M from $3.6M.
- CEO cited strong demand for EksoNR and Indego; final results expected in March 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549084/000143774924000621/0001437749-24-000621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549084/000143774924000621/ekso20240104_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-000621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer